ストックスクリーナーアプリを入手
4.605
0.77%
0.035
前日終値:
$4.57
開ける：
$4.6
24時間の取引高:
92,242
Relative Volume:
0.57
時価総額：
$40.58M
収益：
-
当期純損益:
$-20.74M
株価収益率:
-1.8347
EPS:
-2.51
ネットキャッシュフロー:
$-18.90M
1週間 パフォーマンス:
+14.27%
1か月 パフォーマンス:
+133.76%
6か月 パフォーマンス:
+75.10%
1年 パフォーマンス:
+71.83%
1日の値動き範囲:
$4.60
$4.725
1週間の範囲:
$4.02
$4.8918
52週間の値動き範囲:
$1.81
$4.8918
Lisata Therapeutics Inc Stock (LSTA) Company Profile
LSTA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
4.60 | 40.31M | 0 | -20.74M | -18.90M | -2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.15 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
757.00 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
847.79 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.87 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.29 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lisata Therapeutics Inc (LSTA) 最新ニュース
Deal Watch: Kuva Labs To Go Public Via Merger With Licensing Partner Lisata - Citeline News & Insights
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement By Investing.com - Investing.com South Africa
Lisata regains full rights to certepetide in Greater China region - Investing.com
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement - Investing.com
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - marketscreener.com
Lisata Therapeutics (LSTA) Ends Licensing Agreement with Qilu Ph - GuruFocus
Lisata Therapeutics ends Qilu certepetide collaboration deal - TipRanks
Lisata regains China rights to pancreatic cancer drug - Proactive financial news
Lisata Therapeutics and Qilu Pharmaceutical Terminate License Agreement - TradingView
Cancer drug rights shift: Lisata takes back certepetide in China - Stock Titan
Lisata shares nearly double on buyout offer: Here are the details - MSN
Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals - RTTNews
Lisata Therapeutics to be acquired by Kuva Labs in $4.00-per-share cash deal - MSN
Lisata Therapeutics surges on Kuva Labs takeover proposal carrying hefty premium - MSN
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Kuva Labs to acquire Lisata Therapeutics for $4 per share By Investing.com - Investing.com Nigeria
How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook - Yahoo Finance
Lisata Therapeutics (LSTA) Downgraded by Brookline Capital | LST - GuruFocus
Halper Sadeh Investigates Fairness of Lisata's $4.00 Sale to Kuva Labs - Intellectia AI
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders - The AI Journal
Lisata Shares Nearly Double On Buyout Offer: Here Are The Details - Asianet Newsable
Lisata Therapeutics to be Acquired by Kuva Labs for $4.00 Per Share - citybiz
Kuva Labs, Inc. entered into a binding term sheet to acquire Lisata Therapeutics, Inc. for $36.7 million. - marketscreener.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (NasdaqSNCY), Ventyx Biosciences, Inc. (Nasdaq - GlobeNewswire Inc.
Why Is Lisata Therapeutics Stock Gaining Today? - Benzinga
Dow Surges 300 Points; Netflix Shares Fall After Q4 Results - Benzinga
Market movers: Kraft Heinz, Lisata Therapeutics, Halliburton, Johnson & Johnson... - Proactive financial news
Lisata stock soars after Kuva Labs acquisition offer at 85% premium By Investing.com - Investing.com South Africa
Lisata stock soars after Kuva Labs acquisition offer at 85% premium - Investing.com Australia
Lisata Therapeutics Signs Binding Term Sheet With Kuva Labs - TradingView
Lisata To Be Acquired By Kuva Labs For $4/shr; Stock Soars Over 80% - Nasdaq
Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal - Proactive financial news
Lisata Therapeutics (LSTA) to be Acquired by Kuva Labs for $4 per Share - Intellectia AI
Lisata Therapeutics (LSTA) Agrees to Acquisition by Kuva Labs - GuruFocus
Lisata Therapeutics Agrees To Be Acquired By Kuva Labs In $4/shr Cash Deal - Nasdaq
Lisata Therapeutics to be acquired by Kuva Labs for $4.00 per share in an all-cash tender offer - marketscreener.com
Kuva Labs to acquire Lisata Therapeutics for $4 per share - Investing.com
Lisata Therapeutics To Be Acquired By Kuva Labs For $4.00 Per Share In An All-Cash Tender Offer - TradingView
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Intraday Session - Sahm
How Lisata Therapeutics Inc. (8NE) stock compares with top peersVolatility Index Analysis & Budget Friendly Growth - bollywoodhelpline.com
Aug Highlights: Will Lisata Therapeutics Inc stock benefit from M A - baoquankhu1.vn
Aug Closing: What is Lisata Therapeutics Incs market positionPortfolio Return Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Macro Review: How Lisata Therapeutics Inc. (8NE) stock compares with top peers2025 Short Interest & Accurate Trade Setup Notifications - ulpravda.ru
How Lisata Therapeutics Inc. (8NE) stock benefits from digital adoptionDollar Strength & High Win Rate Trade Alerts - ulpravda.ru
Why Lisata Therapeutics Inc. stock could benefit from AI revolutionMid Cap Growth Trends & Investment Portfolio Recommendations - Улправда
Lisata Ahead Of The Curve: Smart Partnerships, No Debt, And A Data-Rich Period Ahead - RTTNews
Lisata Therapeutics Q3 2025 Earnings Preview - MSN
Retail Trends: Can Lisata Therapeutics Inc 8NE stock deliver consistent EPS growth2025 Retail Activity & Daily Volume Surge Signals - moha.gov.vn
Lisata Therapeutics Inc (LSTA) 財務データ
収益
当期純利益
現金流量
EPS
1.31%
3.45%
大文字化:
|
ボリューム (24 時間):